Table 3.
Clinical Utility of the Combined Biomarker Model*
| VUMC + UC Denver | Mayo Intermediate, Benign Diagnosis (F/U or Biopsy Proven), n = 81 |
||
|---|---|---|---|
| Without CBM | With CBM | Improvement | |
| Procedures, n (%) | Patients | Patients | Patients |
| PET scan (one or more) | 33 (40.7%) | 28 (34.6%) | 5 (6.1%) |
| Bronchoscopy/EBUS + Nav (one or more) | 43 (53.1%) | 34 (41.9%) | 9 (11.2%) |
| Surgical resection/biopsy (one or more)† | 14 (17.3%) | 13 (16%) | 1 (1.3%) |
| Transthoracic needle aspiration (one or more) | 9 (11.1%) | 9 (11.1%) | 0 (0%) |
| Any invasive procedure‡ | 51 (62.9%) | 41 (50.6%) | 10 (12.3%) |
| Mayo Intermediate, Biopsy-proven Cancer Diagnosis, n = 165 | |||
| Follow-up CT (one or more), No. (%) | 85 (51.5%) | 37 (22.4%) | 48 (29.1%) |
| Time to diagnosis (days), median (IQR) | 60 (32–116) | 21 (21–43) | 39 |
Definition of abbreviations: CBM = combined biomarker model; CT = computed tomography; EBUS = endobronchial ultrasound; F/U = follow up; IQR = interquartile range; Mayo = Mayo model; Nav = electromagnetic navigation bronchoscopy; PET = positron emission tomography with fluorodeoxyglucose; UC Denver = University of Colorado Denver; VUMC = Vanderbilt University Medical Center.
Patient data were available in the VUMC and UC Denver cohorts. N represents the number of patients for whom clinical data were available and who were in the intermediate risk group (0.1–0.7 risk) by the prevalence-adjusted Mayo risk model.
Biopsy via bronchoscopic/surgical means, which is distinct from transthoracic/percutaneous needle aspiration.
Any invasive procedure includes bronchoscopy/EBUS plus Nav, surgical resection/biopsy, and transthoracic needle aspiration.